In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sol-Gel Technologies Ltd (NASDAQ: SLGL), with a price target of $21. The company’s shares closed yesterday at $6.43, close to its 52-week low of $6.03.
Selvaraju noted:
“We have valued Sol-Gel based on a discounted cash flow (DCF)-based analysis comprising a risk-adjusted net present value (rNPV) valuation for each of the company’s clinical-stage pipeline candidates.”
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 5.7% and a 48.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.
Currently, the analyst consensus on Sol-Gel Technologies Ltd is a Moderate Buy with an average price target of $21.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.48 and a one-year low of $6.03. Currently, Sol-Gel Technologies Ltd has an average volume of 19.22K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sol-Gel Technologies Ltd. a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.